Skip to content
View in the app

A better way to browse. Learn more.

99NICU

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

Kiovig 10% administration

Featured Replies

Dear colleagues,

In relation to cope with hyperbilirubinemia in term babies, we have managed to order Kiovig 10% Intravenous Immunoglobulin I have had some though time trying to understand the dosage, could you possibly help with the dosage? Do you have protocols for Kiovig?

And also do you have some protocols for so called IVIG usage for neonates?

pharm.png

I am not familiar with this practice and indication, but here are some points that might help you 'connect the dots':

  • This clinical practice guideline by the American Academy of Pediatrics (2022) includes a recommendation for IVIG therapy in Key Action Statements (KAS) 21: "Intravenous immune globulin (IVIG; 0.5 to 1 g/kg) over 2 hours may be provided to infants with isoimmune hemolytic disease (ie, positive DAT) whose TSB reaches or exceeds escalation of care threshold. The dose can be repeated in 12 hours. (Aggregate Evidence Quality Grade C, Option)". However, they state that "The effectiveness of IVIG to prevent the need for an exchange transfusion is unclear."

  • The EMA summary of product characteristics (SPC) for Kiovig 10% does not provide such an indication, but it IS indicated for children 0-18 years of age, which includes neonates (no specific reference to premature neonates, however). In addition, the Paediatric Population subsection under 4.2 Posology states explicitly that "The posology in children and adolescents (0-18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions."

  • For neonatal-specific recommendations for IVIG therapy you may consult the Australasian Neonatal Medicines Formulary (ANMF) monograph for intravenous immunoglobulins, but note that they refer to the product Privigen and not Kiovig, so make sure you note the differences in formulation, rate of administration and other relevant aspects (in our NICU we use Privigen too, in the rare instances we need IVIG therapy).

Hope this helps!

To read the comments in this discussion, please log in or register.

Membership is free and open to neonatal care professionals worldwide.

Log in Join free

To read the comments in this discussion, please log in or register.

Membership is free and open to neonatal care professionals worldwide.

Log in Join free

Hello! I have little to add to Dotans excellent post above, just how we do this - we rarely use immunoglobulines but sometimes opt for this, when there is a DAT-driven hemolytic hyperbili.

We typically give 1g/kg, and start the infusion at 0.3 ml/kg/hour, doubling the infusion rate every half hour up to a max of 4.8 ml/kg/h. So, we end up with a total infusion time of about 3.5 hours.

I attach the XLS-sheet we use , I am sure you can translate with an AI-engine or so )

Privigeninfusionsschema-4.xlsx

To read the comments in this discussion, please log in or register.

Membership is free and open to neonatal care professionals worldwide.

Log in Join free

To read the comments in this discussion, please log in or register. It's free and open to neonatal care professionals worldwide!

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.